The U.S. Food and Drug Administration issued a correction to a September 13, 2023 Federal Register notice (88 FR 62799) that had announced the withdrawal of Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, from sale for safety or effectiveness reasons. The correction indicates that the original notice omitted the determination regarding the related abbreviated new drug applications (AN). No further details about the reasons for withdrawal or the status of the AN applications are provided in the excerpt.
Layer 1 · Fact check
AI analysis
Each claim below was extracted from the reporting and checked against independently retrieved evidence. Expand a claim to see the evidence trail and reasoning.
Layer 2 · Biblical perspective
Biblical interpretation
Produced only after the factual analysis was complete. It examines the specific reported conduct — never a party, nation, or person as a whole — and never alters the factual findings above.
FDA withdrawal of Oxandrin (oxandrolone) tablets for safety or effectiveness
Biblical principle
Justice and prudence call for the protection of the common good and the health of the community (cf. Acts 6:1, Ezekiel 12:19).
Old Testament
“And say to the people of the land: Thus saith the Lord God to them that dwell in Jerusalem in the land of Israel: They shall eat their bread in care, and drink their water in desolation: that the land may become desolate from the multitude that is therein, for the iniquity of all that dwell therein.”
Ezekiel 12:19 (DRV)
Illustrates that collective neglect or wrongdoing can lead to suffering, reminding of the importance of safety measures.
New Testament
“And in those days, the number of the disciples increasing, there arose a murmuring of the Greeks against the Hebrews, for that their widows were neglected in the daily ministration.”
Acts 6:1 (DRV)
Shows early Christian concern for the vulnerable and equitable care, analogous to protecting public health.
Explanation
The supplied factual report concerns a regulatory action on a pharmaceutical product. No specific conduct by individuals is described that can be evaluated against biblical moral teaching. Therefore, there is insufficient scriptural context to render a moral judgment about the action itself.
Why these passages apply
Acts 6:1 illustrates the early church’s concern for the vulnerable (widows) and the need for equitable care, which parallels modern concerns for public health. Ezekiel 12:19 speaks of suffering that results from collective iniquity, reminding that neglect of safety can lead to harm.
Interpretive limitations
Only the provided verses may be cited; no external biblical texts or theological commentary are employed. The connection between the verses and the regulatory action is indirect and illustrative, not definitive.
Source comparison
AI analysis
How each publication covered the same event — facts included, sourcing quality, framing, and omissions.
The FDA is correcting a notice that appeared in the Federal Register of September 13, 2023 (88 FR 62799).
The original notice announced the determination that Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, were withdrawn from sale for reasons of safety or effectiveness.
The correction adds that the abbreviated new drug applications (ANDAs) referencing those tablets were also determined to be withdrawn for safety or effectiveness and will be removed from the Orange Book.
Sourcing
High – the information comes directly from an official FDA correction published in the Federal Register.
Framing
The text is purely factual and corrective; it does not contain opinion or editorial commentary.
Omissions
The notice does not explain the specific safety or effectiveness concerns that led to the withdrawal, nor does it provide details about the impact on patients or prescribers.
Where evidence is thin or reporting diverges, the fact-check entries above say so explicitly rather than manufacturing certainty. Claims marked “Unverifiable” or “Missing context” reflect genuine gaps in the available evidence, not editorial judgment.
Evidence
Fact
Every source the pipeline retrieved, grouped by evidence tier. Repeated reporting of the same original claim is not counted as independent confirmation.
No evidence records published for this event yet.
Methodology
AI analysis
This analysis was produced by an automated daily pipeline: feeds are retrieved and normalized, URLs canonicalized, near-duplicates removed, and articles describing the same underlying event are clustered. Claims are extracted as atomic, testable propositions; evidence is retrieved in tiers from primary sources down to commentary; each claim is verified against that evidence; then reporting analysis and — separately — biblical analysis are performed. Every stage emits validated structured data, and any stage that fails validation is quarantined for human review instead of being published.
Publisher reputation, author reputation, and ideology never determine whether a factual claim is true. The biblical classifier examines only the specific reported conduct, and its result cannot change the factual findings.
AI disclosure
AI-generated analysis.
Evidence checked:
0
Primary sources:
0
Confidence:
Low
Last analyzed:
Oct 7, 2026, 2:40 AM CDT
Pipeline:
2.1.0
Articles in this event
Federal Register · Health, Drug Administration, Human Services Department, Food
